ABL Diagnostics Signs Distribution Agreement with PALEX to Offer Products in Spain
Woippy, France – ABL Diagnostics (FR001400AHX6 – ABLD) announced today the execution of a distribution agreement with PALEX (https://www.palexmedical.com/) to offer ABL Diagnostics products to laboratories in Spain. The agreement allows PALEX to distribute ABL Diagnostics’ molecular biology assays and software for microbiology laboratories.
The collaboration will be carried out through a close partnership with ABL TherapyEdge SL Spain, an affiliate of ABL Diagnostics. The technical and commercial teams of both companies will work together to optimize the user experience for laboratories interested in implementing ABL Diagnostics kits or software in Spain.
“Palex’s extensive experience in the health sector, spanning over 65 years, makes them an ideal partner to offer our products to laboratories in Spain,” said Ronan Boulme, ABL Diagnostics GRC Director. “This partnership will strengthen our presence in the country and be a valuable asset for laboratories looking to access our innovative technology.”
Jaune Clariana, In Vitro Diagnostic Manager at PALEX, added, “The demand for sequencing-based solutions in microbiology laboratories has increased since the COVID-19 pandemic. Through our network of suppliers, Palex can offer end-to-end solutions to hospitals and laboratories involved in managing infectious diseases. This collaboration with ABL Diagnostics and its Spanish affiliate is a strategic asset for the company, and we are proud to join forces to spread the DeepChek® technology in Spain.”
The detailed terms of the agreement have not been disclosed.
ABL Diagnostics (ABLD) is a leading international company that offers innovative molecular biology assays and end-to-end solutions for molecular detection and genotyping. Their products, including UltraGene® for Polymerase Chain Reaction (PCR) and DeepChek® for DNA sequencing, cover a wide range of microbiology applications, with a primary focus on HIV, SARS-CoV-2, tuberculosis, viral hepatitis, and more. ABL Diagnostics’ products are sold worldwide through their own sales team and a network of exclusive distributors.
PALEX, with the support of Apax Partners since 2023 and Fremman Capital since 2021, has been developing innovative solutions for the healthcare sector for over 65 years. Their technology is applied to enhance life and well-being, with a focus on refining the diagnosis, treatment, and monitoring of diseases. PALEX is committed to identifying and evaluating technological innovations that can advance healthcare and creating tailor-made solutions to meet the needs of hospitals, medical centers, and research facilities.
CONTACTS:
ABL Diagnostics
Chalom Sayada
General Manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
PALEX
Jaume Clariana
Specialized Unit Manager
In Vitro Diagnostics
Tel: +34 6 39 65 88 94
j.clariana@palex.es
FORWARD-LOOKING STATEMENT
This press release contains certain implicitly or explicitly forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such statements will be verified, as they are subject to numerous risks, including those set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on ABL Diagnostics’ website (www.abldiagnostics.com). These forward-looking statements are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of all or part of these risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from the statements made in this press release.
This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe to ABL Diagnostics shares, or the solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a violation of applicable laws. Individuals in possession of this press release must inquire about any local restrictions and comply with them accordingly.
Distributed by https://pressat.co.uk/
